Novartis is paying $120 million up front to secure rights to a Monte Rosa molecular glue degrader drug candidate as well as options for two others. The two companies began working together last year under an alliance focused on immune mediated-diseases.
The post Novartis Adds to Its Immunology Prospects With Another Deal for Monte Rosa’s Molecular Glue Drugs appeared first on MedCity News.
